Metronomic Cyclophosphamide and Capecitabine Combined With Bevacizumab in Advanced Breast Cancer

Abstract

Treatment with metronomic capecitabine and cyclophosphamide in combination with bevacizumab was effective in advanced breast cancer and was minimally toxic. The number of baseline CECs significantly correlated with response and outcome, therefore supporting further studies on this surrogate marker for the selection of patients to be candidates for antiangiogenic treatments.